At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
High Dose Fish Oil 1060 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Randomized Double Blind Crossover Study Of Fish Oil [Eicosapentaenoic Acid (EPA) And Docosahexaenoic Acid (DHA)] For Intractable Partial Seizures
National Center for Complementary and Integrative Health (NCCIH)·interventional·Posted Mar 30, 2009·Updated Feb 7, 2014
In Brief
A Phase 2 clinical trial evaluating Placebo, High Dose Fish Oil, and 1 other intervention for Epilepsy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedMar 2009
Primary CompletionMay 2011
Study CompletionAug 2011
TodayJul 2026
First PostedMar 30, 2009
Enrollment StartMay 1, 2008
Primary CompletionMay 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.3 years ago
Interventions
Placebodrug
corn oil (n-6 fatty acids)
High Dose Fish Oildrug
n-3 fatty acids, 1060 mg EPA + DHA
Low Dose Fish Oildrug
n-3 fatty acids, 2160 mg EPA + DHA